The Molecular Diagnostic Core will continue to provide real-time molecular diagnosis for MSLT-II sentinel lymph nodes (SLN) and support the projects of the Program Projects. The major function will be to continue the ?real-time? molecular staging of histopathology(-) SLN of MSLT-II patients for treatment stratification from international and domestic participating sites. To accomplish this major task, the Core will be responsible for processing, purifying, quantifying, cryopreserving, as well as performing multimarker (MM) quantitative realtime RT-PCR (qRT-PCR) assays on MSLT-II paraffin-embedded (PE) SLNs. The results will be immediately utilized by Core B to randomize patients to either the complete lymph node dissection (CLND) arm or routine follow-up arm of the MSLT-II protocol. Results of the MM qRT-PCR SLN staging are provided to Project III and Core A for assessment as well. The Core?s other important functions will be the procurement and isolation of DNA/RNA from PE SLN, non-SLN, primary melanomas and systemic metastasis. Specimens will be accrued from JWCI, and MSLT-I &-II for Projects. The main objective is to provide a centralized Molecular Core facility for processing and storage of RNA and DNA extracted from archival PE/frozen specimens and bloods. To ensure the integrity of samples and the meaningfulness of analysis, the operation and implementation of standard operating procedures (SOPS) for specimen handling, processing, cryostorage, and inventory must be centralized. The Core will offer laser capture microdissection and immunohistochemistry services. Prospectively collected blood from MSLT-II patients will be processed for RNA lysates and DNA, allowing for examination of circulating tumor cells from RNA lysates and circulating tumor-related DNA in serum/plasma, repectively, for Project II. The Core will have a quality assurance program for specimen nucleic acid processing and MM qRT-PCR analysis of MSLT-II SLNs. There will be a central laboratory program for the operation of these multiple tasks. The specimens procured from both MSLT-I &-II patients are invaluable resources for this proposal and future molecular studies.

Public Health Relevance

The Core?s key function is molecular diagnosis and upstaging of SLN for improving detection of cutaneous melanoma metastasis to the SLN. The molecular upstaging of SLN will be validated to improve management of patients. The Core will also provide crucial sewices in collecting, processing, and isolating RNA/DNA from melanoma tumors and lymph nodes for molecular and genomic assays in the program project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA029605-32
Application #
8544994
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
32
Fiscal Year
2013
Total Cost
$692,459
Indirect Cost
$428,341
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Wang, Jinhua; Huang, Sharon K; Marzese, Diego M et al. (2015) Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol 135:532-41
Lessard, Laurent; Liu, Michelle; Marzese, Diego M et al. (2015) The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching. J Invest Dermatol 135:2464-74
Wang, Jinhua; Hua, Wei; Huang, Sharon K et al. (2015) RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb. Oncotarget 6:30165-77
Deutsch, Gary B; Kirchoff, Daniel D; Faries, Mark B (2015) Metastasectomy for stage IV melanoma. Surg Oncol Clin N Am 24:279-98
Faries, Mark B (2015) From the guest editor: The sentinel node: evolution of the revolution. Introduction. Cancer J 21:1-2
Marzese, Diego M; Hoon, Dave Sb (2015) Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn 15:647-64
Faries, M B; Cochran, A J; Elashoff, R M et al. (2015) Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of t Br J Dermatol 172:571-3
Marzese, Diego M; Liu, Michelle; Huynh, Jamie L et al. (2015) Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res 28:82-93
Ono, Shigeshi; Oyama, Takashi; Lam, Stella et al. (2015) A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 6:7053-64
Cochran, Alistair J; Huang, Rong-Rong; Su, Albert et al. (2015) Is sentinel node susceptibility to metastases related to nodal immune modulation? Cancer J 21:39-46

Showing the most recent 10 out of 248 publications